Skip to content

The Research Briefing

The signal beneath the noise.

The GLP-1 conversation moves quickly. The Research Briefing helps distinguish what established clinical research shows, what public-health and regulatory bodies say, and the questions still being studied.

What we know. What we are still learning. The questions that remain.

How to Read This

Evidence deserves context.

A result from a clinical trial is not a promise for every person. A social-media claim is not a substitute for research. And the most important questions are not always answered by a single study.

The Research Briefing shares cited sources, clear context, and a practical distinction between established findings, emerging evidence, and open questions.

  • What We Know

    Established findings from defined studies.

  • What We Are Learning

    Evidence that is still emerging or being tested.

  • What Remains Open

    The real-world questions research has not fully answered.

Latest Updates

FDA Safety Update · November 9, 2026

New GLP-1 warnings about a rare eye condition.

The FDA is requiring warning-label changes for GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). This rare eye condition involves reduced blood flow to the optic nerve and can cause sudden, painless vision loss in one eye, including permanent vision loss.

The FDA advises people with sudden vision loss, blurred or missing areas of vision, or other new visual disturbances to contact a healthcare professional right away. People who develop NAION should discuss with their healthcare professional whether to continue or stop their GLP-1 medicine; this is not a blanket recommendation for everyone to stop treatment.

Read more

This is a regulatory safety update, not a new individual trial. In its analysis of 126 randomized controlled trials, the FDA reported 6.4 probable NAION cases per 100,000 person-years among GLP-1 users, compared with 3.8 among people receiving placebo or a non-GLP-1 glucose-lowering medicine. These rates describe cases over accumulated follow-up time, not a percentage of everyone taking the medicines. Events were rare, and risk factors overlap with conditions common in people using GLP-1 medicines. The evidence does not establish a definitive cause-and-effect relationship.

Read the FDA Safety Communication (opens in a new tab)

This summary is for general education. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service.

Recent Research · October 2026

Beyond weight loss: new evidence in sleep apnea.

An October 2026 publication in the New England Journal of Medicine reported that retatrutide, an investigational medicine targeting three hormone receptors, reduced sleep-apnea severity more than placebo in adults with overweight or obesity and moderate-to-severe obstructive sleep apnea.[9]

Read more

The findings expand the conversation beyond body weight—but they do not establish that every peptide product has the same effects or that this medicine is appropriate for every person.

Investigational therapy · Randomized clinical-trial evidence

Read the study context

Clinical Trial Evidence

The studies behind the conversation.

Landmark trials have changed what is possible in obesity treatment. Understanding what each study measured—and what it did not—matters just as much as knowing the headline result.

  1. 01

    Semaglutide · STEP 1

    A 68-week trial in adults with overweight or obesity without diabetes.[1]

  2. 02

    Tirzepatide · SURMOUNT-1

    A 72-week trial in adults with obesity or overweight plus a weight-related complication, excluding diabetes.[2]

  3. 03

    Semaglutide · SELECT

    A cardiovascular-outcomes trial in adults 45+ with established cardiovascular disease and overweight or obesity, but no diabetes.[3]

The Questions That Remain

Important questions are still being studied.

Long-term treatment, maintenance and discontinuation, lean-mass preservation, access, affordability, quality of unapproved products, and real-world lived experience all require careful attention.

  1. 01

    Long-Term Outcomes

    What do longer-term safety, effectiveness, and use look like across different populations?

    Explored on Day 1: Research Briefing
  2. 02

    Maintenance + Discontinuation

    What helps people maintain benefits, and what happens when treatment changes or stops?

    Explored on Day 2: Town Hall
  3. 03

    Strength + Nutrition

    How can people support lean mass, strength, energy, and adequate nutrition?

    Explored on Day 2: Protecting Muscle
  4. 04

    Access + Equity

    Who can access evidence-based care, and what happens when cost or coverage becomes the barrier?

    Explored on Day 1: Who Pays—and Where Do Patients Go?
  5. 05

    Product Quality

    Why approval status, sourcing, and the difference between approved and unapproved products matter.

    Explored at The Peptide Conference + Expo:Pre-Game to The GLP-1 Summit + Expo Quality and Sourcing

In 2025, WHO issued conditional guidance on GLP-1 therapies for obesity in part because questions remain around long-term evidence, maintenance and discontinuation, cost, and equitable implementation.[5]

Read the Source

Start with evidence. Keep asking better questions.

The Research Briefing links directly to peer-reviewed studies, public-health guidance, and regulatory information. We show the source, explain the context, and distinguish what is established, emerging, and unresolved.

External sources are cited for information and context. Their inclusion does not imply endorsement of, affiliation with, or participation in The GLP-1 Summit + Expo.

Our Standard

Better questions start with better context.

  1. 01

    Cite the Source

    Link to the original study, guideline, or public-health resource whenever possible.

  2. 02

    Show the Context

    State the study population, comparator, timeframe, and meaningful limitations before drawing conclusions.

  3. 03

    Separate Evidence from Opinion

    Label clinical evidence, expert perspective, lived experience, and commercial interpretation clearly.

  4. 04

    Update Responsibly

    Date research items and revise or retire them when stronger evidence or official guidance changes the picture.

Important

Information—not medical advice.

The Research Briefing is for general education and event programming. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service. Decisions about medicines belong with a qualified healthcare professional.

Bring your questions to the room.

Explore the conversations shaping what comes next—or tell us what question belongs in the room.